Solidago Vigaurea for Prostate Cancer Therapy
Abstract
Adenocarcinoma of the prostate is currently the most prevalent cancer in men in the United States and represents 36% of all cancers among men (1). It is estimated that more than 210,000 new cases are diagnosed and 32,000 patients succumb to this disease every year (1). Although patients with localized lesions can be cured by radical prostatectomy or radiotherapy, more than 90% of cancer deaths are attributed to metastatic disease (2). Even those patients who have localized cancer and have been "successfully" treated with surgery often experience "recurrent" disease after many years. In the last two decades, numerous chemotherapeutic agents have been studied. However, the overall results have been quite disappointing. The failure of the current approach to develop an anti-cancer drug for prostate cancer suggests that we need essentially a new approach by defining a specific target molecule in this cancer (3). Traditional screening of anti-cancer drugs has been mostly dependent on growth inhibition assay for cancer cells. However, targeting a specific gene with well-defined clinical rationale will provide a better chance of developing a more effective therapeutic agent.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2011
- Accession Number
- ADA545005
Entities
People
- Kounsouke Watabe
Organizations
- Southern Illinois University